Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de pembrolizumabe com trastuzumabe e quimioterapia em pessoas com câncer esofagogástrico

12 de outubro de 2026 atualizado por: Memorial Sloan Kettering Cancer Center

Um estudo multicêntrico de fase 2 de braço único de pembrolizumabe neoadjuvante com trastuzumabe e quimioterapia em tumores esofagogástricos HER2+ ressecáveis

The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.

Visão geral do estudo

Descrição detalhada

Eligible patients will receive 8 peri-operative cycles of pembrolizumab and trastuzumab with chemotherapy (fluoropyrimidine/oxaliplatin doublet for patients initially enrolled and subsequently FLOT [5-fluorouracil, oxaliplatin and docetaxel] followed by pembrolizumab and trastuzumab maintenance to complete 1 total year of therapy.

Tipo de estudo

Intervencional

Inscrição (Estimado)

49

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Recrutamento
        • Massachusetts General Hospital (Data Collection Only)
        • Contato:
          • Samuel Klempner, MD
          • Número de telefone: 617-724-4000
    • New Jersey
      • Basking Ridge, New Jersey, Estados Unidos, 07920
        • Recrutamento
        • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
        • Contato:
          • Yelena Janjigian, MD
          • Número de telefone: 646-888-4186
      • Middletown, New Jersey, Estados Unidos, 07748
        • Recrutamento
        • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
        • Contato:
          • Yelena Janjigian, MD
          • Número de telefone: 646-888-4186
      • Montvale, New Jersey, Estados Unidos, 07645
        • Recrutamento
        • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
        • Contato:
          • Yelena Janjigian, MD
          • Número de telefone: 646-888-4186
    • New York
      • Commack, New York, Estados Unidos, 11725
        • Recrutamento
        • Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)
        • Contato:
          • Yelena Janjigian, MD
          • Número de telefone: 646-888-4186
      • Harrison, New York, Estados Unidos, 10604
        • Recrutamento
        • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
        • Contato:
          • Yelena Janjigian, MD
          • Número de telefone: 646-888-4186
      • New York, New York, Estados Unidos, 10065
        • Recrutamento
        • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
        • Contato:
          • Yelena Y Janjigian, MD
          • Número de telefone: 646-888-4186
      • Uniondale, New York, Estados Unidos, 11553
        • Recrutamento
        • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
        • Contato:
          • Yelena Janjigian, MD
          • Número de telefone: 646-888-4186
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Ativo, não recrutando
        • University of Pennsylvania (Data Collection Only)
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • MD Anderson Cancer Center (Data Collection Only)
        • Contato:
          • Jennifer Li, MD
          • Número de telefone: 855-760-5921

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age 18 years or older at time of signing informed consent.
  • ECOG performance status 0-1.
  • HER2+ esophageal, GEJ, or gastric adenocarcinoma biopsy or resection specimen as defined by local HER2 IHC3+ or IHC 2+/FISH>2.0 expression.
  • Complete surgical resection of the primary tumor must be achievable
  • Demonstrate adequate organ function as defined in Table 1.

Table 1 - Organ Function Requirements for Eligibility Hematological

  • Absolute neutrophil count (ANC): ≥1,500 /mcL

  • Platelets: ≥100,000 / mcL

  • Hemoglobin: ≥8 g/dL Renal

  • Creatinine clearance: ≥ 50 mL/minute Hepatic

  • Serum total bilirubin: ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN. Except patients with Gilbert's disease (≤3x ULN)

  • AST and ALT: ≤ 2.5 X ULN

  • Albumin: >3 mg/dL Coagulation

  • International normalized ratio (INR) OR prothrombin time (PT) Activated partial thromboplastin time (aPTT): <1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants

  • Male participants: A male participant must agree to use contraception as detailed in Section 15.3 of this protocol during the treatment period and for at least 230 days (5 terminal half-lives of trastuzumab [140] plus an additional 90 days [spermatogenesis cycle]) after the last dose of study treatment and refrain from donating sperm during this period.

  • Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of childbearing potential (WOCBP) as defined in section 15.3 OR
    2. A WOCBP who agrees to follow the contraceptive guidance in section 15.3 during the treatment period and for at least 170 days (140 days plus an additional 30 days [menstruation cycle]) after the last dose of study treatment.

Exclusion Criteria:

  • Presence of metastatic or recurrent disease.

  • Has received prior treatment for esophagogastric cancer

  • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 agent.

  • Has received prior therapy with an anti-HER2 agent

  • Left ventricular ejection fraction <50% within 1 month of screening by MUGA or echocardiogram. Patients with an ejection fraction 45-49% may be permissible in the absence of any cardiac symptoms, if cleared by a cardiologist, and per the investigator's discresion.

  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

  • Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., dexamethasone containing antiemetic regimen or steroids as CT scan contrast premedication) may be enrolled.

  • The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.

  • Has a known history of active TB (Bacillus tuberculosis)

  • Hypersensitivity to pembrolizumab or any of its excipients

  • Has been diagnosed or treated for another malignancy in the past 3 years (not including non-melanoma skin cancer)

  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis

  • Has known history of, or any evidence of active, non-infectious pneumonitis.

  • Has an active infection requiring systemic therapy.

  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.

  • A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

  • Has had an allogeneic tissue or solid organ transplant

  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease; systemic lupus erythematosus; Wegener syndrome [granulomatosis with polyangiitis]; myasthenia gravis; Graves' disease; rheumatoid arthritis, hypophysitis, uveitis) within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:

    • Subjects with vitiligo or alopecia
    • Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment.
    • Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
  • Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).

  • Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

  • Is unwilling to give written informed consent, unwilling to participate, or unable to comply with the protocol for the duration of the study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Esophagogastric Cancer

Participants will have a diagnosis of resectable HER2+ (IHC 3+ or IHC 2+/FISH ratio >2.0) esophageal, GEJ or gastric cancer.

Pembrolizumab will be administered on an every 3-week dosing schedule

Trastuzumab will be administered on an every 3-week dosing schedule

Oxaliplatin every 3 weeks, +/-7 days

Capecitabine twice daily on days 1 to 14 every 3 weeks or 5-FU on days 1 to 5 every 3 weeks

5-Fluorouracil administered as a 24 hour IV continuous infusion once every 2 weeks

Docetaxel administered intravenously once every 2 weeks.

will be collected (optionally)

will be collected (optionally)

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Event-free survival (EFS)
Prazo: 2 years

EFS is defined as the time from start of treatment to time of disease progression, recurrence, or death, whichever occurs first.

2 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de fevereiro de 2024

Conclusão Primária (Estimado)

30 de novembro de 2027

Conclusão do estudo (Estimado)

30 de novembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

3 de novembro de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

3 de novembro de 2023

Primeira postagem (Real)

8 de novembro de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever